Pasithea Therapeutics (NASDAQ:KTTA) Releases Earnings Results, Beats Expectations By $0.01 EPS

Pasithea Therapeutics (NASDAQ:KTTA) posted its quarterly earnings data on Friday. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01, FiscalAI reports.

Pasithea Therapeutics Stock Performance

Pasithea Therapeutics stock traded up $0.00 during mid-day trading on Friday, reaching $0.52. The company’s stock had a trading volume of 2,355,348 shares, compared to its average volume of 558,271. The company has a market capitalization of $17.44 million, a price-to-earnings ratio of -0.33 and a beta of 0.39. Pasithea Therapeutics has a 12 month low of $0.28 and a 12 month high of $2.06. The business’s 50 day simple moving average is $0.48 and its 200 day simple moving average is $0.62.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on KTTA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Pasithea Therapeutics in a research report on Monday, September 21st. Zacks Research cut Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $3.00.

About Pasithea Therapeutics

Pasithea Therapeutics Corp. is a biotechnology company focused on developing treatments for central nervous system (CNS) disorders. Its research has centered on novel therapies for conditions such as depression and other neuropsychiatric diseases, areas in which existing treatments may not provide adequate results for all patients. The company has also pursued psychedelic-based therapeutic approaches and related clinical-development programs. In addition to drug discovery, Pasithea has explored treatment-delivery activities, including ketamine-assisted therapy services through operations associated with its business.